Realta Investment Advisors Sells 650 Shares of Gilead Sciences, Inc. $GILD

Realta Investment Advisors lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 22.6% during the second quarter, HoldingsChannel reports. The fund owned 2,226 shares of the biopharmaceutical company’s stock after selling 650 shares during the quarter. Realta Investment Advisors’ holdings in Gilead Sciences were worth $247,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at approximately $25,000. Activest Wealth Management raised its position in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Gilead Sciences during the 1st quarter valued at $29,000. Colonial Trust Advisors boosted its holdings in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares during the last quarter. Finally, Core Alternative Capital grew its stake in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 241 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. UBS Group raised their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Saturday, September 27th. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Finally, Rothschild & Co Redburn lifted their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.17.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the transaction, the chief executive officer directly owned 591,203 shares in the company, valued at $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the sale, the insider directly owned 113,193 shares in the company, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,000 shares of company stock valued at $9,402,130. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 1.9%

Shares of Gilead Sciences stock opened at $112.69 on Monday. The company’s 50-day moving average price is $114.34 and its 200-day moving average price is $109.97. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12-month low of $83.98 and a 12-month high of $121.83. The company has a market cap of $139.83 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 0.77 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.